Characteristics of included trials
| Characteristic | Results disseminated | ||
| Overall, n=285* | With results, n=41* | Without results, n=244* | |
| Target enrollment | 86 (40–200) | 60 (30–127) | 90 (40–200) |
| Phase | |||
| Not applicable | 109 (38) | 16 (39) | 93 (38) |
| Phase 1 | 13 (4.6) | 1 (2.4) | 12 (4.9) |
| Phase 1/Phase 2 | 13 (4.6) | 1 (2.4) | 12 (4.9) |
| Phase 2 | 46 (16) | 5 (12) | 41 (17) |
| Phase 2/Phase 3 | 16 (5.6) | 2 (4.9) | 14 (5.7) |
| Phase 3 | 38 (13) | 8 (20) | 30 (12) |
| Phase 4 | 50 (18) | 8 (20) | 42 (17) |
| Registry | |||
| Cross-registered | 22 (7.7) | 2 (4.9) | 20 (8.2) |
| ClinicalTrials.gov | 134 (47) | 18 (44) | 116 (48) |
| ChiCTR | 105 (37) | 17 (41) | 88 (36) |
| IRCT | 9 (3.2) | 1 (2.4) | 8 (3.3) |
| EUCTR/EudraCT | 3 (1.1) | 0 (0) | 3 (1.2) |
| RPCEC | 3 (1.1) | 1 (2.4) | 2 (0.8) |
| Registries with <3 trials | 9 (3.2) | 2 (4.9) | 7 (2.9) |
| Countries | |||
| China | 130 (46) | 20 (49) | 110 (45) |
| Iran | 22 (7.7) | 1 (2.4) | 21 (8.6) |
| USA | 19 (6.7) | 1 (2.4) | 18 (7.4) |
| Italy | 11 (3.9) | 4 (9.8) | 7 (2.9) |
| Spain | 9 (3.2) | 1 (2.4) | 8 (3.3) |
| Egypt | 7 (2.5) | 0 (0) | 7 (2.9) |
| France | 7 (2.5) | 0 (0) | 7 (2.9) |
| Multinational | 5 (1.8) | 3 (7.3) | 2 (0.8) |
| Countries with <5 trials | 51 (18) | 9 (22) | 42 (17) |
| No country given | 24 (8.4) | 2 (4.9) | 22 (9.0) |
*Median (IQR); n (%).
ChiCTR, Chinese Clinical Trial Registry; IRCT, Iranian Registry of Clinical Trials; RPCEC, Cuban Public Registry of Clinical Trials.